PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY ROA • Market segmentation by RoA • Comparison by RoA • Oral - Market size and forecast 2018-2023 • Parenteral - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by RoA PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca • Bausch Health • F. Hoffmann-La Roche Ltd • Gilead Sciences, Inc. • Merck & Co., Inc. PART 14: APPENDIX • Research methodology • List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global CMV therapeutics market pipeline: Overview Exhibit 18: Global CMV therapeutics market pipeline: Overview Exhibit 19: RoA - Market share 2018-2023 (%) Exhibit 20: Comparison by RoA Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Oral - Year-over-year growth 2019-2023 (%) Exhibit 23: Parenteral - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Parenteral - Year-over-year growth 2019-2023 (%) Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Others - Year-over-year growth 2019-2023 (%) Exhibit 27: Market opportunity by RoA Exhibit 28: Customer landscape Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in North America Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Europe - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Europe Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in Asia Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Top 3 countries in ROW Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Impact of drivers and challenges Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: AstraZeneca - Vendor overview Exhibit 52: AstraZeneca - Product segments Exhibit 53: AstraZeneca - Organizational developments Exhibit 54: AstraZeneca - Geographic focus Exhibit 55: AstraZeneca - Key offerings Exhibit 56: AstraZeneca - Key customers Exhibit 57: Bausch Health - Vendor overview Exhibit 58: Bausch Health - Business segments Exhibit 59: Bausch Health - Organizational developments Exhibit 60: Bausch Health - Geographic focus Exhibit 61: Bausch Health - Segment focus Exhibit 62: Bausch Health - Key offerings Exhibit 63: Bausch Health - Key customers Exhibit 64: F. Hoffmann-La Roche Ltd - Vendor overview Exhibit 65: F. Hoffmann-La Roche Ltd - Business segments Exhibit 66: F. Hoffmann-La Roche Ltd - Organizational developments Exhibit 67: F. Hoffmann-La Roche Ltd - Geographic focus Exhibit 68: F. Hoffmann-La Roche Ltd - Segment focus Exhibit 69: F. Hoffmann-La Roche Ltd - Key offerings Exhibit 70: F. Hoffmann-La Roche Ltd - Key customers Exhibit 71: Gilead Sciences, Inc. - Vendor overview Exhibit 72: Gilead Sciences, Inc. - Business segments Exhibit 73: Gilead Sciences, Inc. - Organizational developments Exhibit 74: Gilead Sciences, Inc. - Geographic focus Exhibit 75: Gilead Sciences, Inc. - Key offerings Exhibit 76: Gilead Sciences, Inc. - Key customers Exhibit 77: Merck & Co., Inc. - Vendor overview Exhibit 78: Merck & Co., Inc. - Business segments Exhibit 79: Merck & Co., Inc. - Organizational developments Exhibit 80: Merck & Co., Inc. - Geographic focus Exhibit 81: Merck & Co., Inc. - Segment focus Exhibit 82: Merck & Co., Inc. - Key offerings Exhibit 83: Merck & Co., Inc. - Key customers Exhibit 84: Validation techniques employed for market sizing

AstraZeneca Bausch Health F. Hoffmann-La Roche Ltd Gilead Sciences, Inc. Merck & Co., Inc.